-
Product Insights
NewNet Present Value Model: Lumos Pharma Inc’s Oratrope
Empower your strategies with our Net Present Value Model: Lumos Pharma Inc's Oratrope report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLumos Diagnostics Holdings Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Lumos Diagnostics Holdings Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Lumos Diagnostics Holdings Ltd (Lumos) is a biotechnology company that designs, develops, manufactures, and markets point-of-care diagnostic tests. The company uses its patented direct sampling micro-filtration and direct multi-planar chromatography (DMC) technology to develop various tests. Its product portfolio includes FebriDx, a test that uses a fingerstick blood sample to support differentiate viral from a bacterial acute febrile...
-
Innovation Ranking
Innovation Ranking – Lumos Pharma Inc
Lumos Pharma Inc (Lumos Pharma), formerly NewLink Genetics Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of new therapies for the treatment of unmet medical needs of rare diseases. The company’s lead investigating candidate, LUM-201 (ibutamoren) is an oral growth hormone stimulating therapy for the treatment of pediatric growth hormone deficiency (PGHD), turner syndrome, children born small for gestational age (SGA), and other rare endocrine disorders. Lumos Pharma is headquartered in Austin, Texas, the US.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VH-4011499A in Human Immunodeficiency Virus (HIV) Infections (AIDS)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VH-4011499A in Human Immunodeficiency Virus (HIV) Infections (AIDS) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VH-4011499A in Human Immunodeficiency Virus (HIV) Infections...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibutamoren Mesylate in Growth Hormone Deficiency
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibutamoren Mesylate in Growth Hormone Deficiency report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibutamoren Mesylate in Growth Hormone Deficiency Drug Details: Ibutamoren...
-
Product Insights
Image Guided Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Image Guided Surgery Pipeline Market Report Overview Image Guided Surgery devices use real-time images during surgery to assist surgeons in precisely guiding the surgical instruments to the anatomic structures. It helps minimize the chances of errors and reduce the procedure time. The Image Guided Surgery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-802 in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-802 in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-802 in Glioblastoma Multiforme (GBM) Drug Details: NLG-802 is under development...
-
Product Insights
NewGrowth Disorders – Drugs In Development, 2024
Empower your strategies with our Growth Disorders – Drugs In Development, 2024 report and make more profitable business decisions. Growth disorders are problems that prevent children from developing normal height, weight, sexual maturity or other features. Very slow or very fast growth can sometimes signal a gland problem or disease. The pituitary gland makes growth hormone, which stimulates the growth of bone and other tissues. Children who have too little of it may be very short. Treatment with growth hormone can...
-
Product Insights
NewIdiopathic Short Stature – Drugs In Development, 2024
Empower your strategies with our Idiopathic Short Stature – Drugs In Development, 2024 report and make more profitable business decisions. Idiopathic short stature is a condition in which the height of the individual is more than 2 standard deviations below the corresponding mean height for a given age, sex, and population, in whom no identifiable disorder is present. It can be subcategorized into familial and non-familial ISS, and according to pubertal delay. The Idiopathic Short Stature drugs in development market research...
-
Product Insights
NewEpendymoma – Drugs In Development, 2024
Empower your strategies with our Ependymoma – Drugs In Development, 2024 report and make more profitable business decisions. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms...